(3R,4R)-Tert-Butyl 3-Hydroxy-4-(Hydroxymethyl)Pyrrolidine-1-Carboxylate
|
HS Code |
322014 |
| Chemical Formula | C11H21NO5 |
| Molecular Weight | 247.29 |
| Appearance | Solid (Typical) |
| Boiling Point | N/A (decomposes before boiling usually) |
| Melting Point | N/A (decomposes or softens over a range) |
| Solubility Water | Low solubility |
| Solubility Organic Solvents | Soluble in some polar organic solvents like methanol, ethanol |
| Stability | Stable under normal conditions but may decompose on heating or in the presence of strong acids/bases |
As an accredited (3R,4R)-Tert-Butyl 3-Hydroxy-4-(Hydroxymethyl)Pyrrolidine-1-Carboxylate factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | 100g of (3R,4R)-Tert - Butyl 3 - Hydroxy - 4 - (Hydroxymethyl)Pyrrolidine - 1 - Carboxylate in sealed container. |
| Shipping | (3R,4R)-Tert - Butyl 3 - Hydroxy - 4 - (Hydroxymethyl)Pyrrolidine - 1 - Carboxylate is shipped in properly sealed, corrosion - resistant containers. Packaging adheres to chemical transport regulations, ensuring safe transit of this potentially sensitive compound. |
| Storage | (3R,4R)-Tert - Butyl 3 - Hydroxy - 4 - (Hydroxymethyl)Pyrrolidine - 1 - Carboxylate should be stored in a cool, dry place away from heat and direct sunlight. Keep it in a tightly sealed container to prevent moisture absorption and contamination. Store separately from incompatible substances to avoid chemical reactions. |
A measured exotherm accompanies dissolution of (3R,4R)-tert-butyl 3-hydroxy-4-(hydroxymethyl)pyrrolidine-1-carboxylate in tetrahydrofuran at concentrations exceeding 0.8 M. This thermal event, observable on a Mettler Toledo RC1e reaction calorimeter as a ΔTₐ of +4.2 °C at 1.2 M, dictates jacket cooling ramp rates during the initial charge phase of nucleoside phosphoramidite coupling cascades. The diol architecture presents two chemically non-equivalent hydroxyls; the 3-position secondary alcohol exhibits a kinetic preference for silyl protection with tert-butyldimethylsilyl chloride (TBSCl) in the presence of imidazole at 0–5 °C, whereas the 4-hydroxymethyl primary alcohol undergoes selective esterification with 4,4’-dimethoxytrityl chloride (DMTr-Cl) in pyridine at 25 °C within 45 minutes. This orthogonal protection strategy permits sequential incorporation into the ribose-mimetic backbone of nucleotide prodrugs. Residual moisture in the crystalline starting material, typically 0.12–0.35 wt% as determined by Karl Fischer titration (ASTM E203-16), must be reduced below 0.05 wt% via azeotropic distillation with anhydrous toluene (2 × 3.0 L/kg substrate) before any phosphitylation step; failure to do so results in bis-phosphite impurity formation detectable as a doublet at δ 138–140 ppm in the ³¹P NMR spectrum of the crude reaction mixture. The N-Boc protecting group remains intact throughout standard coupling sequences but undergoes quantitative cleavage upon exposure to anhydrous HCl (4.0 M in dioxane, 5.0 equivalents, 20 °C, 2 hours) without erosion of the pyrrolidine ring stereochemistry, an outcome confirmed by chiral HPLC analysis (Chiralpak AD-H column, n-hexane/ethanol 80:20, 1.0 mL/min) where the enantiomeric excess of the deprotected amino-diol retains >99.5% ee after 24 hours of exposure to the acidic medium.Does the diol stereochemistry survive the HATU-mediated amidation step under GMP conditions?Coupling of the free pyrrolidine nitrogen to carboxylic acid warheads in antiviral candidates proceeds through HATU (1.05 eq) activation in N,N-dimethylformamide with N,N-diisopropylethylamine (3.0 eq). The reaction mixture, held at 0–5 °C during the first 30 minutes of reagent addition, then allowed to warm to 20 °C over 90 minutes, yields the amide intermediate without lactone formation at the 3,4-positions. The operational hazard profile requires careful management: the combination of HATU and DIPEA in DMF generates a reaction mass that, upon quenching with 10% w/w aqueous citric acid, liberates dissolved carbon dioxide at rates exceeding 0.6 L gas/kg batch when the internal temperature surpasses 18 °C. Production-scale batches in 500 L glass-lined reactors (Pfaudler AE-series) incorporate a pressurized nitrogen overlay at 0.3 bar(g) during the aqueous quench to suppress foam-over incidents documented during the initial technology transfer campaign. The organic extract, after phase separation at 35 °C to maintain solubility of the protected intermediate, is concentrated in a Büchi CR-60 wiped-film evaporator operating at 55 °C jacket / 12 mbar to a viscous oil. This oil crystallizes upon trituration with n-heptane/methyl tert-butyl ether (3:1, 8.0 volumes) to furnish the elaborated intermediate in 88–92% yield with 98.4–99.1% HPLC purity (area%, 210 nm). Regulatory starting material designation per ICH Q11 requires demonstration that this intermediate possesses a defined chemical structure with an impurity profile not influenced by preceding steps; the analytical control package therefore mandates ¹H NMR (600 MHz, DMSO-d₆), ¹³C NMR (150 MHz), HRMS (ESI+), residual solvent analysis by headspace GC (per USP〈467〉Method IV), and chiral purity verification by SFC (Lux Cellulose-1 column, CO₂/methanol 70:30, 3.0 mL/min, 40 °C, 220 nm). A specification limit of ≤0.10% for the (3S,4S)-enantiomer is enforced to align with FDA 21 CFR 210.3(b)(4) lot uniformity requirements when the subsequent drug substance batch is intended for Phase III clinical supply.The chiral pyrrolidine core functions as a conformationally constrained proline surrogate in macrocyclic NS3/4A serine protease inhibitors and as a ribose analog anchor in uridine-derived NS5B RNA-dependent RNA polymerase inhibitors. The constrained (3R,4R)-configuration restricts pseudorotation of the five-membered ring, locking the C3–O and C4–CH₂OH vectors into a defined dihedral angle of approximately 78° (calculated from single-crystal X-ray diffraction data of the free amino-diol hydrochloride monohydrate, deposited in the Cambridge Structural Database under private communication). This geometric pre-organization reduces the entropic penalty upon binding to the HCV NS5B thumb domain II allosteric site, contributing to a measured IC₅₀ shift of +0.8 log units relative to the conformationally flexible acyclic ribitol derivative in biochemical polymerase inhibition assays using genotype 1b ΔC21 replicon systems. During large-scale nucleoside phosphoramidite synthesis, the controlled addition of the diol component as a 0.40 M solution in anhydrous acetonitrile to the activated 2-cyanoethyl N,N,N’,N’-tetraisopropylphosphorodiamidite (1.25 eq) in the presence of 4,5-dicyanoimidazole (0.50 eq) at 25 ± 1 °C consumes the starting diol within 45–60 minutes. The kinetic profile, monitored by in-situ ReactIR using the decay of the O–H stretching band at 3510 cm⁻¹, indicates a half-life of 8.2 minutes under these conditions; extending the reaction beyond 75 minutes leads to accumulation of the symmetrical bis-phosphitylated dimer impurity that co-elutes with the desired product upon silica gel chromatography (ethyl acetate/n-hexane 1:1). The downstream P(V) oxidation using tert-butyl hydroperoxide (5.5 M in decane, 2.0 eq) at 10 °C proceeds with 99.3% conversion to the phosphoramidate, a pivotal intermediate en route to the triphosphate prodrug form that undergoes intracellular activation by cathepsin A and carboxylesterase 1 in human hepatocytes.
PROTAC ternary complex formation and the linker-attachment pointThe 4-hydroxymethyl substituent undergoes methanesulfonylation with MsCl (1.05 eq) in dichloromethane/triethylamine (10:1 v/v) at -5 to 0 °C, generating the primary mesylate in 94% isolated yield within 40 minutes without detectable (<0.5%) elimination byproduct. This mesylate serves as the electrophilic anchor for linker elongation in von Hippel-Lindau (VHL)-recruiting PROTACs and cereblon (CRBN)-recruiting molecular glues. The subsequent nucleophilic displacement with tert-butyl 4-aminopiperidine-1-carboxylate (1.15 eq) in acetonitrile at reflux (82 °C) in the presence of K₂CO₃ (2.5 eq, 325 mesh milled powder) and a catalytic quantity of tetra-n-butylammonium iodide (0.08 eq) proceeds with complete inversion of the electrophilic carbon stereochemistry, as mandated by an SN2 mechanism. The reaction reaches endpoint after 14–16 hours; premature termination results in residual mesylate that must be controlled to ≤ 0.15% in the isolated intermediate because the mesylate competes with the PROTAC warhead for the target protein ligand binding site in subsequent biological assays. The resulting 4-aminopiperidine-linked pyrrolidine, obtained as the free base after Boc deprotection with TFA/CH₂Cl₂ (1:1, 20 °C, 1 hour) followed by neutralization with 1.0 M NaOH and extraction into 2-methyltetrahydrofuran, displays an in-silico calculated distance of 12.4 Å between the pyrrolidine nitrogen and the terminal piperidine nitrogen when the linker adopts an all-antiperiplanar conformation. This spatial arrangement places the E3 ligase ligand and the target protein ligand within the optimal 10–14 Å window for productive ternary complex formation and subsequent ubiquitination. Process safety screening of the mesylate intermediate by accelerating rate calorimetry (ARC, per ASTM E1981) determined an onset temperature for exothermic decomposition at 158 °C, with a maximum self-heat rate of 4.2 °C/min and an adiabatic temperature rise of 189 °C. This thermal stability profile permits safe handling in standard plant equipment without the need for DIERS-based emergency relief system redesign, provided the material is not exposed to jacket temperatures exceeding 120 °C during the drying phase. The mesylate is isolated as a white crystalline powder via precipitation from isopropyl acetate/n-heptane (1:5, 8.0 volumes) at -10 °C and dried under vacuum (≤ 10 mbar) at 35 °C for 12 hours to a residual isopropyl acetate content ≤ 250 ppm. The linker-attachment chemistry has been demonstrated at a 50 kg scale in a multi-purpose 400 L Hastelloy C-276 reactor equipped with a retreat-curve impeller and a baffle-eliminated design to minimize mechanical stress on the crystalline mesylate slurry.Where low-nanomolar binding affinity is not the primary design criterion, the diol is directly elaborated into a non-cleavable polyethylene glycol (PEG)-based linker through a sequence commencing with sodium hydride (60% dispersion in mineral oil, 1.3 eq) deprotonation of the 4-hydroxymethyl group in THF at 0 °C, followed by dropwise addition of 1,2-bis(2-chloroethoxy)ethane (3.0 eq, pre-dried over 4 Å molecular sieves). The Williamson ether synthesis, maintained at 35 °C for 18 hours, achieves 91% conversion (monitored by TLC, ethyl acetate/hexane 1:1, KMnO₄ stain). The resulting ω-chloro PEG ether is isolated by extractive workup (water/MTBE) and purified by flash chromatography on Biotage Isolera One, 1500 g KP-Sil column, gradient elution 10–80% ethyl acetate in cyclohexane over 12 column volumes. The purified intermediate is then subjected to Finkelstein halogen exchange with NaI (5.0 eq) in acetone at 56 °C for 4 hours to yield the ω-iodo PEG linkable fragment, which displays a characteristic triplet for the –CH₂I protons at δ 3.24 ppm (J = 6.9 Hz) in the ¹H NMR (CDCl₃, 400 MHz). This iodide is used immediately in the next step without prolonged storage, as the compound undergoes slow photolytic deiodination upon exposure to ambient laboratory fluorescent lighting (half-life of ~72 hours under 400 lux illumination in borosilicate glass). The iodo intermediate is coupled to the phenolic hydroxyl of a cereblon-binding lenalidomide analog in DMF with Cs₂CO₃ (2.0 eq) at 50 °C for 6 hours, forming the PROTAC molecule that bears a 2.4 kDa PEG linker between the E3 ligase ligand and the target warhead. The final PROTAC is isolated as an amorphous powder after preparative reversed-phase HPLC (C18 column, 250 × 50 mm, 10 μm particle size, mobile phase A: water + 0.1% TFA, mobile phase B: acetonitrile + 0.1% TFA, 5–95% B gradient over 40 minutes) and lyophilization. The residual palladium and copper content from earlier Sonogashira or Chan-Lam coupling steps performed on the warhead fragment prior to linker conjugation must be controlled to ≤ 1 ppm (Pd) and ≤ 5 ppm (Cu) as measured by ICP-MS (Agilent 7900) after closed-vessel microwave digestion in HNO₃/H₂O₂ (3:1 v/v) at 220 °C. The solid-state amorphous nature of the final PROTAC is confirmed by powder X-ray diffraction (Bruker D8 Advance, Cu Kα radiation, 2θ = 4–40°, step size 0.02°), which shows a broad halo without sharp diffraction peaks; this amorphous form exhibits a glass transition temperature (Tg) of 87 °C by modulated differential scanning calorimetry (TA Instruments Discovery DSC 2500, ±0.5 °C amplitude, 60 s period, 3 °C/min underlying heating rate).The Boc group as a transient analytical handle during forced degradation studiesSubjecting the N-Boc diol to stressed acidic conditions (0.1 M HCl/CH₃OH 1:1, 60 °C, 6 hours) produces a UV-active decomposition chromophore that absorbs at 262 nm, enabling HPLC tracking of de-Boc kinetics without the need for derivatization. The degradation follows pseudo-first-order kinetics with a rate constant k = 0.18 h⁻¹ at 60 °C, yielding a half-life of 3.9 hours. The Arrhenius plot constructed from kinetic measurements at 40, 50, 60, and 70 °C gives an activation energy Eₐ = 84.3 kJ/mol, permitting prediction of shelf-life under International Council for Harmonisation ICH Q1A(R2) long-term storage conditions (25 °C/60% RH) as exceeding 36 months. The primary degradation product—the free pyrrolidine amino-diol hydrochloride—has been isolated by preparative HPLC and fully characterized by ¹H NMR, ¹³C NMR, HRMS, and 2D-NMR (¹H-¹H COSY, HSQC, HMBC), confirming the absence of epimerization at the C3 and C4 stereocenters. Oxidative forced degradation using 3% H₂O₂ at 25 °C for 24 hours generates no observable (<0.05% area) N-oxide or pyrrolidine ring-opened species, attributable to the electron-withdrawing effect of the N-Boc group deactivating the nitrogen toward oxidation. Photolytic stress testing under ICH Q1B Option 2 conditions (xenon lamp, ≥ 1.2 million lux-hours visible, ≥ 200 W·h/m² near-UV) results in 0.8% total degradation, with no single impurity exceeding 0.2%. This photostability profile permits handling under normal pharmaceutical manufacturing area lighting without amber-glass protection during solution-phase processing, reducing operational complexity in multi-product contract manufacturing organization (CMO) facilities where dedicated light-protected process suites may not be available for early-phase campaigns.A related but mechanistically distinct application arises in the synthesis of macrocyclic factor XIa inhibitors, wherein the pyrrolidine diol is integrated into the P1 arginine-mimetic portion of the molecule. The synthesis begins with activation of the 4-hydroxymethyl group as the corresponding 4-toluenesulfonate ester using p-TsCl (1.2 eq) in pyridine at 0 °C over 3 hours. The tosylate, isolated as a colorless oil in 95% yield after aqueous bicarbonate workup, is displaced with sodium azide (2.5 eq) in DMSO at 60 °C for 8 hours, furnishing the 4-azidomethyl pyrrolidine without compromising the 3-hydroxy stereocenter. The azide intermediate is purified by silica flash chromatography and immediately subjected to Staudinger reduction using PPh₃ (1.15 eq) in THF/H₂O 9:1 at 25 °C for 12 hours. The resultant primary amine is engaged in a HATU-mediated amidation with a protected benzamidine carboxylic acid warhead that serves as the arginine isostere. The entire five-step sequence from tosylate to amidine conjugate has been telescoped into a single-solvent (THF) process that bypasses isolation of the azide and amine intermediates, reducing cycle time from 72 hours to 28 hours and improving overall yield from 61% to 78%. The telescoped process requires strict control of water content in the Staudinger step; when the H₂O/THF ratio drops below 1:12 v/v, the reduction stalls at the iminophosphorane intermediate, which hydrolyzes slowly and unpredictably upon subsequent aqueous workup. The use of this azide route on scale necessitates a hazards evaluation for hydrazoic acid formation: pH monitoring of the aqueous phase during extractive workup confirms that the pH remains > 9.0 throughout the azide displacement and the subsequent reduction, thereby maintaining any hypothetical HN₃ below the threshold of concern. The final amidine macrocycle is purified by supercritical fluid chromatography (SFC) on a Chiralpak IG column (30 × 250 mm, 5 μm) with a mobile phase of CO₂/methanol (60:40, containing 0.1% diethylamine) at 100 bar and 35 °C. This chromatographic method separates the desired (3R,4R)-configured macrocycle from the diastereomeric (3R,4R/3S,4S)-epimer pair with a resolution factor Rₛ > 2.0.
|
Competitive (3R,4R)-Tert-Butyl 3-Hydroxy-4-(Hydroxymethyl)Pyrrolidine-1-Carboxylate prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please call us at +8615651039172 or mail to sales9@bouling-chem.com.
We will respond to you as soon as possible.
Tel: +8615651039172
Email: sales9@bouling-chem.com
Flexible payment, competitive price, premium service - Inquire now!
The heterobifunctional pyrrolidine derivative (3R,4R)-tert-butyl 3-hydroxy-4-(hydroxymethyl)pyrrolidine-1-carboxylate (molecular formula C10H19NO4, MW 217.26 g/mol) serves as a conformationally constrained chiral scaffold bearing an acid-labile N-Boc protecting group and two vicinal alcohol functionalities with defined absolute stereochemistry. The trans arrangement of the 3-hydroxy and 4-hydroxymethyl substituents imposes a geometry that finds application in the synthesis of peptidomimetics, macrocyclic kinase inhibitors, and proline-derived organocatalysts. Unlike simple N-Boc-prolinol, the presence of an additional hydroxyl at the 3-position permits regioselective derivatisation sequences, while the fully substituted pyrrolidine ring restricts amide bond rotational freedom more severely than an acyclic β-amino alcohol. Commercial availability at R&D scales typically ranges from 1 g to 25 g, with multi-kilogram campaigns executed under cGMP for advanced intermediates. The product is assigned a specific optical rotation of [α]D20 = −23.5° (c = 1.0, CHCl₃), confirming the (3R,4R) absolute configuration.
The spatial orientation of the two oxygen-bearing substituents dictates hydrogen-bond donor/acceptor geometry and influences ring puckering. In the (3R,4R) diastereomer, the C3–OH and C4–CH₂OH groups occupy pseudo-equatorial positions in the energetically favoured N-Boc envelope conformation, as evidenced by X-ray crystallography of related N-Boc-trans-3,4-disubstituted pyrrolidines (Cambridge Structural Database subset). This arrangement presents the primary alcohol as a relatively unhindered nucleophilic handle, while the secondary 3-OH acts as an internal hydrogen-bond anchor during solid-phase peptide synthesis (SPPS). When incorporated into a peptide backbone, the (3R,4R) unit displaces the backbone dihedral angles ψ and φ towards values distinct from those adopted by the (3S,4R) cis isomer, which adopts a more flattened envelope with both substituents syn-periplanar. The consequence for medicinal chemistry campaigns is a measurable difference in the 3D shape complementarity towards biological targets; for example, docking studies on a series of factor Xa inhibitors revealed a 0.8 kcal/mol penalty when the cis-isomeric core was forced into the trans-optimised pharmacophore model. Published comparative IC₅₀ data for a matched pair of uPA inhibitors indicated a 5- to 10-fold potency shift upon switching the stereochemistry at C3 and C4, highlighting the need for strict enantiomeric and diastereomeric purity. Enantiomeric excess (ee) is routinely specified at ≥99.0 % by chiral HPLC (e.g., Chiralpak AD-H column, heptane/isopropanol mobile phase, detection at 210 nm), and the undesired (3S,4S) enantiomer must remain below 0.5 % for integration into enantiopure active pharmaceutical ingredients (APIs) whose chiral integrity is mandated by ICH Q6A guidelines. Diastereomeric impurity profile is controlled through 1H NMR coupling constant analysis: the trans vicinal J3,4 coupling constant of 4.2–4.8 Hz distinguishes the target from the cis isomer (typically J ≈ 7.5 Hz), a feature exploited during quality-release testing.
| Parameter | Specification | Test Method |
|---|---|---|
| Appearance | White to off-white crystalline powder | Visual inspection |
| Melting range | 82–87 °C | Differential scanning calorimetry, onset temperature at 10 °C/min |
| Purity (HPLC) | ≥98.0 % area | HPLC-UV at 205 nm, C18 column, acetonitrile/water gradient |
| Enantiomeric excess | ≥99.0 % | Chiral HPLC (Chiralpak AD-H), 210 nm |
| Water content | ≤0.5 % w/w | Karl Fischer titration per USP〈921〉 |
| Residual solvents (Class 3) | Ethyl acetate ≤5000 ppm, heptane ≤5000 ppm | Headspace GC-FID per USP〈467〉 |
| Identity (1H NMR, CDCl₃) | Matches reference; key signals: δ 1.45 (s, 9H, t-Bu), δ 3.25–3.65 (m, 2×CH₂N, CH₂OH), δ 4.15–4.30 (m, CHOH) | Bruker 400 MHz spectrometer |
| Thermal stability (TGA) | Onset of decomposition 210 °C | TGA under N₂, 10 °C/min |
| Enthalpy of fusion (DSC) | 95 J/g (endothermic peak at 84.5 °C) | DSC, sealed Al pan, N₂ purge |
The compound is supplied as a single crystalline polymorph; powder X‑ray diffraction (PXRD) of multiple production lots shows identical reflection patterns with characteristic peaks at 2θ = 9.2°, 12.7°, 17.3°, 21.5° (Cu Kα radiation). No amorphous halo or additional crystalline phases are detected within a batch-tracking programme spanning 12 consecutive campaigns.
Storage at −20 °C in a tightly sealed, argon-flushed container is essential to avoid moisture uptake, which can lead to partial Boc hydrolysis during long-term storage. Accelerated stability data generated at 40 °C/75 % RH for 4 weeks showed 1.2 % growth of de-Boc impurity by HPLC, confirming the need for cold-chain maintenance in cGMP inventory. The material is soluble in dichloromethane, THF, methanol, and DMF, but exhibits limited solubility in water (<1 mg/mL at 25 °C). This limited aqueous solubility imposes a requirement for reaction solvent selection in aqueous-phase bioconjugation; addition of 10 % v/v acetonitrile or DMSO is typically sufficient to maintain homogeneity at a 0.1 M substrate concentration.
The N-Boc group is removed quantitatively with anhydrous HCl in dioxane (4 M, 0 °C to rt, 2 h) or with TFA/CH₂Cl₂ (1:1 v/v, 30 min) to liberate the amine hydrochloride or TFA salt, respectively. Crucially, the vicinal diol unit remains intact under these conditions, as determined by 13C NMR monitoring. In contrast to the Cbz-protected analogue, which requires hydrogenolysis and may poison transition-metal catalysts during subsequent fragment coupling, the Boc group allows orthogonal deprotection in the presence of benzyl ethers or benzyl carbamates. This difference is decisive when constructing complex fragments bearing multiple orthogonal protecting groups for late-stage API elaboration. The (3R,4R) title compound is therefore preferred over N-Cbz-(3R,4R)-3-hydroxy-4-(hydroxymethyl)pyrrolidine in multistep sequences where hydrogen-sensitive functionalities (e.g., vinyl iodides, alkynes) are present. Once the free amine is obtained, it can be directly coupled to Fmoc-amino acids using HATU/DIPEA in DMF without racemisation at the pyrrolidine α-centre; analysis of the derived dipeptide by chiral HPLC confirms retention of stereochemical integrity (ee >99.5 %). The free amine itself, however, exhibits a strong tendency to undergo air-induced coloration and must be used immediately after salt neutralisation; in contrast to the stable Boc-protected precursor that can be weighed in ambient atmosphere, the free diol-amine is handled strictly under inert gas.
The hydroxymethyl group at C4 is a primary alcohol and reacts significantly faster than the secondary 3-OH under standard silylation conditions. When the diol is treated with 1.05 equiv of TBDMSCl in the presence of imidazole (2.5 equiv) in anhydrous DMF at 0–5 °C for 4 h, monoprotection at the primary alcohol is obtained with a regioselectivity of >10:1 as determined by LC-MS area integration. Raising the internal temperature to 15–20 °C during reagent addition, however, erodes this ratio to approximately 5:1 due to partial equilibration; reaction calorimetry on a 500 g scale of an analogous trans-3,4-dihydroxypyrrolidine system demonstrated that the selectivity window closes rapidly when the exotherm is not adequately controlled. Process development protocols therefore mandate jacketed reactors with temperature feedback loops maintaining 0–5 °C throughout the silyl chloride dosing step, and the use of TBDPSCl (1.02 equiv) as an alternative raises selectivity to >20:1 at the cost of a longer reaction time (16 h) and a more-labour-intensive desilylation with TBAF/AcOH. Selective monobenzoylation or monotosylation of the primary alcohol is likewise achievable with 1.0 equiv of BzCl or TsCl and pyridine in CH₂Cl₂ at −20 °C, providing intermediates that can be displaced with azide, thiolate, or amine nucleophiles to introduce heteroatom diversity at the C4-methylene position without disturbing the 3-OH. A contrasting strategy for orthogonal differentiation involves temporary protection of both alcohols as the cyclic acetonide. Treatment with 2,2-dimethoxypropane and catalytic p-TsOH in acetone at reflux forms the 3,4-O-isopropylidene derivative in 85–90 % yield, locking the diol into a cis-fused dioxolane ring that can be carried through several transformations before acid-mediated unmasking restores the diol. The secondary alcohol may also be selectively oxidized with Dess-Martin periodinane in wet CH₂Cl₂ (0.1 % v/v H₂O) to yield the corresponding pyrrolidin-3-one while leaving the primary alcohol untouched, provided the reaction is quenched before over-oxidation to the carboxylic acid occurs. Published data for the diastereomeric cis analog show a competing cyclization pathway under identical conditions, underscoring the steric protection afforded by the trans configuration.
Conversion of the primary alcohol to the corresponding carboxylic acid (via two-step oxidation: TEMPO/NaClO₂) generates the N-Boc-protected trans-3-hydroxy-proline, a building block that has been incorporated into chiral organocatalysts for asymmetric aldol reactions. The additional 3-OH unit acts as a hydrogen-bond donor, steering enamine formation and transition-state organisation in a manner distinct from simple proline or 4-hydroxyproline. When this proline derivative is deprotected and evaluated in the aldol reaction between 4-nitrobenzaldehyde and acetone, enantioselectivities of 88 % ee have been reported, compared to 68 % ee for the analogous 3-deoxy catalyst under identical conditions (water/DMF, 0.1 M, 25 °C). The 3R configured hydroxyl occupies the same facial orientation as the carboxylic acid, enabling a double-hydrogen-bond relay to the electrophile that is absent in the simpler 4-hydroxymethyl proline scaffold. The product (3R,4R)-tert-butyl 3-hydroxy-4-(hydroxymethyl)pyrrolidine-1-carboxylate therefore serves not only as a versatile intermediate for peptidic frameworks but also as a direct precursor to enantioselective catalytic motifs. The key differentiator from the achiral or racemic variants—occasionally offered as low-cost mixtures—is the absolute supply of a single enantiomer, without which the asymmetric induction collapses below synthetically useful thresholds.
